
Background
Because uncontrolled growth of blood vessels (angiogenesis) contributes to the progression of diverse diseases from cancer to macular degeneration, drugs targeting the neovasculature are obvious candidates to control unwanted vascularization and tumor growth. However, most anti-angiogenic drugs must be taken up into the target cell in order to exert their effects. The availability of a potent drug that tackles angiogenesis via a different mode presents a valuable therapeutic strategy for diseases that depend on abnormal neovasculature.
Technology Description
University researchers have synthesized a novel lipopeptide, Somocystinamide A (ScA), which is a synthetic version of a compound isolated from marine cyanobacteria. ScA is distinguished by a lipophilic structure similar to native membrane components and this unique structure enables ScA to directly integrate into cellular membranes, perturb normal lipid homeostasis and selectively activate caspase 8, leading to programmed cell death.
Applications
The promise of anti-angiogenic drugs in is reflected in the plethora of clinical trials. The obvious applications are reflected in the distribution of ~3000 human anti-angiogenesis trials:
~85% are designed to treat various forms of cancer and
~10% are for macular degeneration and a other eye diseases (e.g., choroid & retinal diseases)
Advantages
Advantages of ScA include:
- A bioactive lipopeptide that can directly integrate into lipophilic structures such as liposomes, thus acting a bioactive structural component. This does not require active uptake into the liposome interior, and leaves the interior free for other cargo.
- Excellent potency, with an IC50 of 0.5pM against human endothelial cells and 80nM in zebra fish;
- Long, lipophilic hydrocarbon chains are readily formulated into liposomes, which can be further customized and or targeted.; and
- Combination therapy whereby ScA melts into the liposomal bilayer and additional anti-cancer drug(s) can be loaded into the liposomal lumen.In sum, ScA's unique, lipophilic structure confers improved functionality and efficacy, which may greatly improve the therapeutic window over other, anti-angiogenic drugs.
State Of Development
ScA has been incorporated into stable, liposomal nanoparticles of 100 nM in size, which retain full potency and excellent activity in vitro and in vivo. In vivo, ScA blocks endothelial cell tube formation and developmental angiogenesis in zebrafish models.
ScA:
- induces apoptosis selectively via caspase 8 activation and in vivo studies confirm that a single local dose of ScA (500ng/kg) inhibits the growth of both caspase 8-expressing and deficient tumors via action on vascular cell caspase-8.
- inhibits tube formation in HUVEC/matrigel model of angiogenesis at pM concentrations.
- experiments assessing activity of Ag-ScA conjugates are in process.
Related Materials
- www.marinebiotech.org — 05/11/2012
- Discovery of Natural Antiangiogenic Leads — 05/11/2012
- Wrasidlo, W., et al., The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8. Proc Natl Acad Sci U S A, 2008. 105(7): p. 2313-8. — 02/19/2008
- Suyama, T.L. and W.H. Gerwick, Stereospecific total synthesis of somocystinamide A. Org Lett, 2008. 10(20): p. 4449-52. — 02/13/2008
- Nogle, L.M. and W.H. Gerwick, Somocystinamide A, a novel cytotoxic disulfide dimer from a Fijian marine cyanobacterial mixed assemblage. Org Lett, 2002. 4(7): p. 1095-8. — 04/04/2002
Similar innovations
- Treatment of Cancer by Inducing Cell Apoptosis
- Synthetic polypeptides for treating and preventing diseases characterized by excess cell proliferation, such as mesenchymally derived cells.
- Read more
-
San Diego, CA, United States
- Diagnostic Test for Cancer Susceptibility
- The technology comprises diagnostic methods to detect mutations of the CDK4I gene as well as detecting deficiencies in the expression products of the gene. In addition, the technology also provides for the detection of mutations and altered gene product o
- Read more
-
San Diego, CA, United States
- Treatment of Liver Fibrosis by Induction of Stellate Cell Apoptosis
- An approach to the treatment of chronic liver disease based on an endogenous peptide targeting the stellate cells. Using standard delivery, the peptide triggers apoptosis only in the stellate liver cells responsible for liver fibrosis, but sparing hepatoc
- Read more
-
San Diego, CA, United States
- Methods of Tissue Repair, Regeneration, and Tissue Engineered Compositions
- A method of propagating ureteric bud (UB) cells in culture under conditions that induce the UB to undergo branching morphogenesis in order to generate a population of UB comprising tubular branches, subdividing the UB population, and resuspending each sub
- Read more
-
San Diego, CA, United States